13:25–14:00

Medical Crossfire® NATALEE, monarchE and OPTIMA: Can We Safely De-escalate Chemotherapy While Escalating CDK4/6 Therapy?

Meteb

Meteb

Esam Murshid

14:00–14:15

Show Me the Data Can Oral SERDs Replace Aromatase Inhibitors in Early Breast Cancer? If Yes, How Should They Be Implemented?

Ahmed Alshehri

14:15–14:30

Panel Discussion

14:30–15:00

Satellite Symposium

15:00–15:15

Coffee Break & Exhibition Visit

15:15–15:45

Show Me the Data DESTINY-Breast05, DESTINY-Breast11, KATHERINE and CompassHER2: Redefining Curative HER2 Therapy — Who Needs Carboplatin, and When, in HER2-Positive Disease?

Alwabari

Bassam

15:45–15:55

TROP2-Directed ADCs in HR+/HER2− Metastatic Breast Cancer: Positioning in the Post-CDK4/6 Era

Omalkhair

15:55–16:10

State-of-the-Art Update | Lightning Round Top ASCO, ESMO and SABCS 2026 Practice-Changing Trials

Dr. Sabah

16:10–16:25

Panel Discussion

16:25–16:35

Coffee Break & Exhibition Visit

16:35–16:55

Medical Crossfire® DESTINY-Breast09: Is THP Still Relevant in First-Line HER2-Positive Metastatic Breast Cancer?

Refaei

Hulayel Alharbi

16:55–17:10

Who Still Needs Anthracyclines in Early-Stage Breast Cancer Across All Subtypes?

Aydah Alawadhi

17:10–17:25

Clinical Pearls DESTINY-Breast06 in HER2-Low and HER2-Ultralow Disease: Which Patients Truly Benefit from ADCs as First-Line Therapy?

Sherif Sammani

17:25–17:45

Multidisciplinary Tumor Board Neuro-Oncology Tumor Board

Mohannad Alsuhaibani

Noha Jastenyah

Sharif

Sherif

Altwairqi

Bu Haliga

Essam

17:45–18:00

Panel Discussion

18:00–19:00

Dinner & Networking — End of Day 1

08:00–08:20

Medical Crossfire® First-Line PD-L1-Negative TNBC: Should ADCs Replace Chemotherapy?

Hashem Alhasheam

Khaled Alsaleh

08:20–08:35

Optimizing Adjuvant Therapy for Premenopausal Women: Strategies to Maintain Persistence of Adjuvant Endocrine Therapy

Altwairqi

08:35–08:45

Panel Discussion

08:45–09:15

Satellite Symposium

09:15–09:30

Sentinel Node Biopsy vs. Targeted Axillary Dissection After Neoadjuvant Chemotherapy for cN1 Disease

Amal Alhefdhi

09:30–09:45

Management of Locoregional Breast Cancer Recurrenc

Nora Trablesi

09:45–10:00

Axillary Management After Neoadjuvant Chemotherapy: What Matters and Why?

Noha Jastenyeah

10:00–10:10

Is Omission of Sentinel Node Biopsy Ready for Routine Use?

Dr Mosbah

10:10–10:20

Coffee Break & Exhibition Visit

10:20–10:50

Satellite Symposium

10:50–11:10

Targeting the PI3K/AKT/mTOR Pathway After CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: Biomarker-Driven Treatment, Optimal Sequencing, and the Emerging Role of Triplet Therapy

Dr. Abdulrahman Aljameeli

11:10–11:20

GLP-1 Receptor Agonists in Breast Cancer: Clinical Takeaways for Breast Oncologists

Dr. Ali Alzahrani

11:20–12:20

Lunch & Networking

12:20–12:40

Medical Crossfire® Post-Neoadjuvant Immunotherapy in TNBC: Standard for All or Selective Use?

Meshari Alzahrani

Dr. Sabah

12:40–13:10

Satellite Symposium

13:10–13:25

Oral SERDs After CDK4/6 Inhibitor Progression: Practice-Changing or Incremental Advance? SERENA-6 Debate: To Be or Not to Be?

Dr Ahmed Alwabari

13:25–13:35

Coffee Break & Exhibition Visit

13:35–14:00

Satellite Symposium

14:00–14:30

Molecular Tumor Board HR+/HER2− Metastatic Breast Cancer: ESR1, ctDNA, PI3K, AKT and ADC Sequencing

Swidan

Alshinnag

Adher

Meteb

Dr. Sabah

Dr. Akhtar

Kauser

Mehari

14:30–16:30

Consensus Statements

16:30–16:40

Closing Remarks